Global Anti-Obesity Drugs Market

1. Summary

The Global Anti-Obesity Drugs Market was valued at $55.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 22.5% CAGR, to an estimated market size of $152 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global anti-obesity drugs market encompasses pharmacological interventions specifically designed for weight management, including GLP-1 receptor agonists, GIP modulators, and amylin analogues. The scope includes prescription-based injectables and emerging oral formulations used to treat obesity (BMI ≥30) and related comorbidities, while excluding over-the-counter supplements, bariatric surgical devices, and lifestyle-only programs.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Anti-Obesity Drugs Market in the period 2025-30:

• The rapid transition from a duopoly to a highly competitive landscape is driven by the entry of next-generation multi-agonists and biologics from major pharmaceutical players.
• The introduction of oral GLP-1 pills starting in late 2025 is expected to significantly expand the market by removing cold-chain requirements and improving patient adherence.
• Clinical expansion into comorbidity management for conditions like cardiovascular disease, sleep apnea, and chronic kidney disease is broadening the eligible patient base and supporting reimbursement.
• Significant supply chain investments are being made by manufacturers to resolve chronic shortages and meet the unprecedented global consumer-led demand.
• The loss of exclusivity for early-generation semaglutide in emerging markets like China and Brazil by 2026 will trigger a surge in generic and biosimilar volume.
• A shift in payer coverage dynamics is occurring as public health systems and private insurers weigh the high cost of treatment against the long-term economic burden of obesity.
• The integration of digital health platforms and AI-powered personalization is enhancing patient engagement and optimizing dosage plans for long-term weight maintenance.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: